Vaccine composition comprising an antigen and a peptide having adjuvant properties
View Patent ↗The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R 1 —XZXZ N XZX—R 2 , whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R 1 and R 2 are selected independently one from the other from the group consisting of —H, —NH 2 , —COCH 3 , —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R 2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.
1. A method of enhancing a patient's adaptive immune response to an antigen comprising:
obtaining at least one antigen;
obtaining at least one peptide comprising a sequence H-KLKLLLLLKLK-H (SEQ ID NO:1; and
administering the antigen and the peptide to a patient.
2. The method of claim 1 , wherein the antigen and the peptide are administered to the patient in a single pharmaceutical composition.
3. The method of claim 1 , wherein the patient is a human.
4. The method of claim 1 , wherein the antigen and the peptide are administered to the patient once.
5. The method of claim 1 , wherein the antigen and the peptide are administered to the patient repeatedly.
6. The method of claim 1 , wherein the antigen and the peptide are administered subcutaneously.
7. The method of claim 1 , wherein the antigen and the peptide are administered intra-muscularly.
8. The method of claim 1 , wherein between 0.1 to 1,000 μg of the antigen are administered.
9. The method of claim 1 , wherein between 0.1 to 1,000 μg of the peptide are administered.
10. The method of claim 1 , wherein enhancing the patient's adaptive immune response to the antigen comprises enhancing uptake of the antigen into an antigen presenting cell.
11. The method of claim 2 , further comprising adding at least one further immune response stimulating substance to the single pharmaceutical composition.
12. The method of claim 2 , further comprising adding at least one immunostimulatory nucleic acid to the single pharmaceutical composition.
13. The method of claim 12 , wherein the immunostimulatory nucleic acid is an oligodeoxynucleotide containing deoxyinosine, an oligodeoxynucleotide containing deoxyuridine, an oligodeoxynucleotide containing at least one CG motif, or an inosine and cytidine containing nucleic acid molecule.
14. The method of claim 2 , further comprising adding at least one cytokine to the single pharmaceutical composition.
15. The method of claim 2 , further comprising adding at least one polycationic peptide or human growth hormone to the single pharmaceutical composition.